tradingkey.logo

Trevi Therapeutics Announces Positive Topline Results From Its Phase 2a RIVER Trial Of Haduvio For Treatment Of Patients With RCC

ReutersMar 10, 2025 10:06 AM

- Trevi Therapeutics Inc TRVI.O:

  • TREVI THERAPEUTICS INC: HADUVIO MET PRIMARY ENDPOINT

  • TREVI THERAPEUTICS: ANNOUNCE POSITIVE TOPLINE RESULTS FROM ITS PHASE 2A RIVER TRIAL OF HADUVIO FOR TREATMENT OF PATIENTS WITH RCC (N=66)

  • TREVI THERAPEUTICS: PATIENT REPORTED & OTHER SECONDARY OUTCOMES WERE STATISTICALLY SIGNIFICANT & CONSISTENT WITH PRIMARY ENDPOINT

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

Tradingkey
KeyAI